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Abstract
Background: Apical membrane antigen 1 (AMA1) is one of the best-studied blood-stage malaria vaccine candidates. When
an AMA1 vaccine was tested in a malaria naı ¨ve population, it induced functionally active antibodies judged by Growth
Inhibition Assay (GIA). However, the same vaccine failed to induce higher growth-inhibitory activity in adults living in a
malaria endemic area. Vaccination did induce functionally active antibodies in malaria-exposed children with less than 20%
inhibition in GIA at baseline, but not in children with more than that level of baseline inhibition.
Methods: Total IgGs were purified from plasmas collected from the pediatric trial before and after immunization and pools
of total IgGs were made. Another set of total IgGs was purified from U.S. adults immunized with AMA1 (US-total IgG). From
these total IgGs, AMA1-specific and non-AMA1 IgGs were affinity purified and the functional activity of these IgGs was
evaluated by GIA. Competition ELISA was performed with the U.S.-total IgG and non-AMA1 IgGs from malaria-exposed
children.
Results: AMA1-specific IgGs from malaria-exposed children and U.S. vaccinees showed similar growth-inhibitory activity at
the same concentrations. When mixed with U.S.-total IgG, non-AMA1 IgGs from children showed an interference effect in
GIA. Interestingly, the interference effect was higher with non-AMA1 IgGs from higher titer pools. The non-AMA1 IgGs did
not compete with anti-AMA1 antibody in U.S.-total IgG in the competition ELISA.
Conclusion: Children living in a malaria endemic area have a fraction of IgGs that interferes with the biological activity of
anti-AMA1 antibody as judged by GIA. While the mechanism of interference is not resolved in this study, these results
suggest it is not caused by direct competition between non-AMA1 IgG and AMA1 protein. This study indicates that anti-
malaria IgGs induced by natural exposure may interfere with the biological effect of antibody induced by an AMA1-based
vaccine in the target population.
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Introduction
WHO estimates there were 243 million malaria cases and 0.9
million deaths in 2008; the vast majority of deaths occurred in
African children less than 5-years old due to Plasmodium falciparum,
which is the most virulent species of human malaria [1]. While the
protective mechanisms remain to be elucidated, a passive transfer
study has shown the importance of gamma-globulin against blood-
stages of P. falciparum [2]. To control and eventually eradicate
malaria, an effective vaccine is considered to be needed, in
addition to the existing tools, such as drugs, insecticides, etc. [3].
Apical membrane antigen 1 (AMA1) is the one of the best-
studied blood-stage vaccine candidates and it is an essential
protein for parasite invasion of an erythrocyte [4]. The invasion
process is complicated (i.e., initial attachment, reorientation, tight
junction formation and internalization), and different studies have
suggested different roles for AMA1: binding to erythrocytes [5–7],
reorientation [8], or internalization [9]. In addition to erythrocyte
invasion, a recent study suggests that AMA1 is involved in
sporozoite invasion of hepatocytes [10]. These results indicate the
AMA1 protein may have multiple roles. Many studies have shown
that AMA1 vaccination can induce protective immunity in animal
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(the monkeys were challenged with P. falciparum). In the monkey
challenge model, anti-AMA1 antibody levels induced by a vaccine
before challenge have shown to correlate with protection [12,13].
In addition to the animal data, many, but not all, epidemiological
studies suggest a high level of AMA1 antibodies is associated with a
reduced risk of malaria [11]. Based on these findings, multiple
AMA1 Phase 1 trials [14–24] and a Phase 2 field trial [25] have
been conducted and published. However, to date no significant
protective effects have been shown in the target population of
African children.
An in vitro parasite Growth Inhibition Assay (GIA; also referred
to as the Invasion Inhibition Assay, IIA) is one of the few widely-
used biological assays that can measure the functional activity of
antibodies against blood-stage malaria. While it is still controver-
sial whether the activity measured by the GIA (IIA) reflects
protective immunity induced by a vaccine, the assay has been used
in preclinical and clinical studies as one of the immunological
readouts. Not only anti-AMA1 antibodies induced by malaria
infection [26,27], but also antibodies induced by AMA1
immunization in malaria naı ¨ve individuals show growth-inhibitory
activity in the in vitro GIA [14,16,19,21–23].
In contrast, while the same AMA1 vaccine increased the anti-
AMA1 antibody levels when it was administered to adults who
lived in a malaria endemic area, the vaccine did not change the
parasite growth-inhibitory activity [15]. In a previous study, we
purified total IgGs from sera collected in an epidemiological study
in Mali (majority of the sera were collected from adults) and
separated the IgGs by affinity chromatography into an AMA1-
binding fraction (AMA1-specific) or an IgG fraction that does not
bind to AMA1 (non-AMA1 IgG). Previously we have shown that
the non-AMA1 IgG, more specifically a fraction of the non-AMA1
IgG which can bind to malaria extract, reduced the functional
activity of the AMA1 antibodies from U.S. vaccinees [27].
Interference by the non-AMA1 IgG induced by malaria infections
likely explains the reason why the AMA1 vaccine did not induce
higher growth-inhibitory activity in the Malian adults in the
vaccine trial. Because limited volumes of sera were collected from
children in the epidemiological study, we could not investigate
whether there was such ‘‘interfering’’ IgG in the children, who are
the main target population of the blood-stage vaccine and who
have less previous exposure to malaria.
Our recent Phase 2 trial in Malian children showed that there
was a small, but significant, increase of growth-inhibitory activity
when data from all AMA1-immunized children was analyzed (the
GIA was performed with total IgGs in the study) [28]. The level of
increase in the activity was not different from the level observed in
U.S. adults who were immunized with the same vaccine
formulation [28]. In the U.S. vaccine trial, all of the volunteers
showed negligible levels of inhibition before vaccination, and after
immunization the growth-inhibitory activity of total IgG was a
function of anti-AMA1 titer. However, in the Malian children, the
increase of growth-inhibitory activity was observed only in AMA1-
immunized children who had less than 20% inhibition before
vaccination. None of the children who had more than 20%
inhibition before vaccination (14/89 children in the AMA1-
immunized group) showed more than a 20% increase, while
antibody levels measured by ELISA increased in most of the
children. On the other hand, out of the remaining 75 children with
less than 20% inhibition before vaccination, 25 (33%) children had
more than a 20% increase after vaccination. In the present study
we wished to investigate the effect of non-AMA1 IgGs in the
children to determine whether similar interference effects could be
identified. Therefore, we made multiple pools of total IgG,
separated them into AMA1-specific and non-AMA1 IgGs, and
tested them by GIA. The non-AMA1 IgGs showed an interference
effect on growth-inhibitory activity.
Materials and Methods
Clinical trials and blood collections
The details of the U.S. adult Phase 1 trial [16] and the Phase 2
trial in Malian children [25] have been supplied elsewhere
(NCT00344539 and NCT00341250). In brief, adults 18–45 years
of age were enrolled in the U.S. trial and they were immunized
on Days 0, 28 and 56 with 20 or 80 mg of AMA1-C1 (a mixture
of the recombinant AMA1-FVO and AMA1-3D7 proteins)
formulated on AlhydrogelH and mixed with CPG 7909. Plasma
samples from individuals with high levels of anti-AMA1 antibody
(as determined by ELISA) on Day 70 were collected 3 months
after the final vaccination. For the Mali trial, Malian children 2–3
years old were enrolled and immunized on Days 0 and 28 either
with 80 mg of AMA1-C1 on AlhydrogelH or a comparator
vaccine (HiberixH). Blood samples were collected on Days 0 and
42. Both trials were conducted under Investigational New Drug
Applications reviewed by the U.S. Food and Drug Administra-
tion. The U.S. Phase 1 trial was reviewed and approved by the
Institutional Review Boards (IRB) of the National Institute of
Allergy and Infectious Diseases (NIAID), National Institutes of
Health (NIH) and by the University of Rochester Research
Subjects Review Board. Written informed consent was obtained
from all volunteers. The Mali Phase 2 trial was reviewed and
approved by the IRB of NIAID at NIH and by the Ethics
Committee of the Faculty of Medicine, Pharmacy and Dentistry,
University of Bamako. Community consent was obtained at a
meeting with village leaders, heads of families, and other
community members prior to the start of the Phase 2 study.
Individual informed consent was then obtained after oral
translation of the consent form into the local language.
Understanding of the contents of the consent was confirmed by
means of a multiple choice questionnaire. Parents or guardians
unable to read placed an imprint of his/her finger in place of a
signature; an independent witness also signed all consent forms.
Total, AMA1-specific and non-AMA1 IgG preparations
Total IgGs were purified from individual plasma samples from
the U.S. trial (n=5) and normal U.S. sera (n=2) using Protein G
columns as described previously [14]. Similarly, total IgG was
prepared from each plasma sample collected on Days 0 and 42
from the Mali Phase 2 trial. All of the total IgGs were dialyzed
against RPMI 1640 and concentrated to 40 mg/ml. Because the
volume of the total IgG from each individual Malian child was not
enough to perform AMA1-specific IgG purification, the total IgG
samples were ranked based on their anti-AMA1(3D7) antibody
level as judged by ELISA and were divided into 3 or 4 groups to
make pooled IgGs at each time point as follows: For Day 0 IgGs
(regardless of immunization groups), D0-1, D0-2, D0-3 and D0-4;
for Day 42 IgGs from HiberixH-vaccinated children, Hib-1, Hib-2
and Hib-3; for Day 42 IgGs from AMA1-vaccinated children,
AMA1-1, AMA1-2 and AMA1-3. The number of individual total
IgGs used to make each total IgG pool and the antibody level of
the pool is shown in Table 1. Although all of the anti-malarial
antibody in Day 0 IgGs and Day 42 IgGs from the Hiberix group
was induced by natural infection, it is possible that vaccination
with HiberixH and/or the timing of blood collection during the
malaria transmission season might alter the immune response.
Therefore, we made separate pooled IgGs from Day 0 IgGs and
Day 42 IgGs from HiberixH group in this study.
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or AMA1(FVO)-specific IgGs and non-AMA1(3D7) or non-
AMA1(FVO) IgGs were prepared individually using AMA1(3D7)
or AMA1(FVO) protein immobilized on Sepharose 4 Fast Flow
columns as described previously [27]. During the affinity purifica-
tion process for each total IgG, the flow-through fraction was
reloaded to the same AMA1-immobilized column three times to
increase the efficacy of separation. Both AMA1-specific IgGs and
non-AMA1 IgGs were dialyzed against RPMI 1640 and concen-
trated to 150,300 ml (AMA1-specific IgGs) or 40 mg/ml (non-
AMA1 IgGs) of final product. Because of the limitations of volumes
available, AMA1(3D7)-specific/non-AMA1(3D7) IgGs were not
prepared from D0-2 or D0-3 total IgG pools.
ELISA
The standardized methodology for performing the ELISA has
been described previously [29]. The absorbance of each test
sample was converted into ELISA units using a standard curve
generated by serially diluting the standard in the same plate. The
ELISA units of each sample were then converted to mg/ml using a
conversion factor as described elsewhere [30]. The minimal
detection level of the AMA1 antibody in this study was 4 mg/ml,
and all responses below that limit of detection were assigned a
value of 2 mg/ml for the analysis.
For the competition ELISA, a fixed amount of total IgG from a
U.S. vaccinee (designated as US-total IgG), which gives approx-
imately an O.D. value of 3 (approximately 30–40 mg/ml of total
IgG in ELISA well), was mixed with 2-fold dilutions of non-
AMA1(3D7) IgGs from Malian children (ranging from 2 to
133 mg/ml in ELISA well). The mixtures were tested by ELISA
using an AMA1(3D7) or AMA1(FVO)-coated plate using the
standard ELISA procedure, and the direct O.D. value was used as
a final readout, instead of ELISA units.
GIA
The standard methodology for the GIA has been described
previously [14]. The assay was performed with purified IgGs at
indicated concentrations against the 3D7 or FVO strain of P.
falciparum parasites.
For the mixture GIA experiment, 4 mg/ml of non-AMA1(3D7)
or non-AMA1(FVO) IgGs were mixed with US-total IgG. The
concentration of US-total IgG was determined at which the IgG
was expected to give ,60% inhibition in the final mixture in the
standard GIA. The growth-inhibitory activity of mixtures was
determined using the standard GIA.
Statistical analysis
The correlation between the two data sets (e.g., anti-AMA1
antibody level and % inhibition in GIA, etc.) was tested by a
Spearman rank correlation test. Best-fit formulations of the GIA
data were calculated using logarithm-transformed antibody levels.
To evaluate interference effect of non-AMA1 IgG, delta %
inhibition was calculated as follows:
Delta % inhibition = (% inhibition of the US-total IgG alone) –
(% inhibition of a mixture of a non-AMA1 IgG and US-total IgG).
Data were analyzed using Prism 5 (GraphPad Software, Inc.,
CA, USA) and p values less than 0.05 were considered significant.
Results
Characteristics of AMA1-specific and non-AMA1 IgGs
from Malian children
We began with the affinity purification of AMA1-specific and
non-AMA1 IgGs in order to evaluate the growth-inhibitory
activity of the AMA1-specific fractions and to assess the possibility
of interfering antibodies in the non-AMA1 IgGs from the Malian
children. The antibody levels of each total IgG pool and non-
AMA1(3D7)/AMA1(FVO) IgG were measured by ELISA and the
results are shown in Table 1. The non-AMA1 IgGs had less than
10% of AMA1 antibody levels compared to the corresponding
original total IgG pools. These results showed that the AMA1-
specific purification method used in this study was efficient.
We then investigated the biological activity of the AMA1-
specific IgGs from U.S. vaccinees and Malian children by GIA
Table 1. Anti-AMA1 antibody level [mg/ml] in test IgGs (40 mg/ml).
AMA1-3D7
b AMA1-FVO
c
n
a Total IgG pool Non-AMA1 (3D7) IgG Total IgG pool Non-AMA1 (FVO) IgG
D0-1 93 2
d 2
d (ND
g)
f 2
d 2
d (ND
g)
D0-2 38 6 N/A
e 82
d (ND
g)
D0-3 46 35 N/A
e 63 2
d (ND
g)
D0-4 27 439 13 (3) 675 19 3
Hib-1 47 2
d 2
d (ND
g)2
d 2
d (ND
g)
Hib-2 33 10 2
d (ND
g)1 6 2
d (ND
g)
Hib-3 35 246 7 (3) 334 8 (2)
AMA1-1 31 66 4 (6) 100 9 (9)
AMA1-2 41 260 16 (6) 354 17 (5)
AMA1-3 41 751 24 (3) 1,050 47 (4)
aNumber of individual IgGs to make total IgG pool.
bAntibody level [mg/ml] to AMA1(3D7) ELISA plate.
cAntibody level [mg/ml] to AMA1(FVO) ELISA plate.
dLess than the minimal detection level of antibody.
eN/A, No sample available.
fNumbers in parentheses, percent relative to the total IgG.
gND, Percent cannot be determined.
doi:10.1371/journal.pone.0020947.t001
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from U.S. vaccinees showed a significant correlation between
antibody level and percent inhibition when they were tested
against the homologous strain of parasites (Spearman rank
correlation, p,0.001, rs =0.96, 95% confidence interval (CI)
0.91–0.99 for 3D7; p,0.001, rs =0.83, 95% CI 0.60–0.94, for
FVO) and the relationship followed a symmetrical sigmoid curve
when the antibody levels were log transformed (r
2=0.93 for 3D7
and 0.82 for FVO). The AMA1-specific IgGs from Malian
children showed almost the same level of growth-inhibitory
activity at the same level of antibody in the GIA well, regardless
of which pools of total IgG were tested. When the data from all
AMA1-specific IgGs from Malian children were combined, there
were significant correlations between antibody levels by ELISA
and percent inhibition in GIA (for 3D7, p,0.001, rs =0.97, 95%
CI 0.92–0.99; for FVO, p,0.001, rs =0.94, 95% CI 0.86–0.98),
and each relationship followed a symmetrical sigmoid curve
(r
2=0.99 for 3D7, 0.94 for FVO). These results indicate that there
was no obvious difference in biological activity of antibodies
among AMA1-specific IgGs induced by an AMA1 vaccination
(IgGs from U.S. vaccinees), by natural infection (IgGs from D0-1,
2, 3 & 4 and Hib-1, 2 & 3 pools) and by both natural infection and
vaccination (IgGs from AMA1-1, 2 & 3 pools).
We next evaluated the activity of non-AMA1 IgGs from Malian
children by GIA at two different concentrations in GIA well using
homologous strain of parasites (i.e., non-AMA1(3D7) IgGs were
tested against 3D7 strain of parasites and non-AMA1(FVO) IgG
with FVO parasites). The % inhibition of non-AMA1 IgG was
plotted against that of the original total IgG pool (Figure 2). The
slope of the best-fit line is 0.97 (95%CI: 0.81–1.14) for the 3D7
data set and 0.87 (95%CI: 0.64–1.10) for FVO. Since the slope
was not significantly different from 1, it showed that the depletion
of AMA1-specific IgGs from the total IgG did not materially
change growth-inhibitory activity, even though AMA1-specific
IgGs from the same total IgG pools also showed activity (Figure 1).
Non-AMA1 IgGs interfere with AMA1 IgG activity in GIA
To assess interference effect in the non-AMA1 IgGs, non-
AMA1 IgGs were tested by GIA either by themselves or in the
presence of total IgG from a U.S. vaccinee (US-total IgG) against
homologous strain of parasites (i.e., non-AMA1(3D7) IgGs were
tested with or without US-total IgG using 3D7 strain of parasites
in GIA, and non-AMA1(FVO) IgGs were similarly tested using
FVO parasites). The US-total IgG was also tested alone as a
positive control (black bar in Figure 3). The non-AMA1 IgGs
showed less than 20 % inhibition at 4 mg/ml (Figure 3). The
mixtures of non-AMA1 IgGs and US-total IgG displayed lower
inhibition for both 3D7 and FVO parasites compared to the US-
total IgG alone. To evaluate the strength of the interference effect
of each non-AMA1 IgG, the difference between US-total IgG
alone and the mixture was calculated (delta % inhibition). As
shown in Figure 4, the non-AMA1 IgGs purified from total IgG
pools with higher AMA1 antibody levels showed greater
interference (larger delta % inhibition) than those from total IgG
pools with lower titer. When all of the data were combined, there
was a significant correlation between the AMA1 antibody level in
the original total IgG pool and the interference effect of non-
AMA1 IgG (Spearman rank correlation, p=0.021, rs =0.80 for
3D7; p=0.003, rs =0.82 for FVO).
To test whether the interfering effect of non-AMA1 IgGs was due
to the blocking of binding between AMA1 antigen and anti-AMA1
antibody, competition ELISA was performed. A fixed amount of
US-total IgG was mixed with seriallydiluted non-AMA1 IgGs which
showed a higher interference effect in Figure 3 (i.e., D0-4, Hib-3 and
AMA1-3). The mixtures were applied to AMA1(3D7) or
AMA1(FVO)-coated ELISA plates as primary antibodies and the
amount of antibodies which bound to AMA1 protein was measured.
The mixture with 14 mg/ml of non-AMA1(3D7) IgG in this ELISA
using AMA1(3D7)-coated plates had the same ratio of US-total IgG
and non-AMA1(3D7) IgG as tested in Figure 3 by GIA using 3D7
strainofparasites, and 11 mg/ml ofnon-AMA1(FVO) IgGfor FVO.
As shown in Figure 5, none of the non-AMA1 IgGs tested blocked
bindingofanti-AMA1antibodyinUS-totalIgGtotheELISAplates.
The same assay was conducted using total IgG from another U.S.
vaccinee and also showed no competition (data not shown). Thus it
does not appear that the interfering effect is due to direct inhibition
of the anti-AMA1 antibodies binding to the plate antigen.
Discussion
In the present study, we have shown that the non-AMA1 IgGs
from Malian children interfere with the growth-inhibitory activity
Figure 1. Strong correlation between anti-AMA1 antibody level and the growth-inhibitory activity in AMA1-specific IgGs. Anti-
AMA1(3D7) (A) or anti-AMA1(FVO) (B) antibody levels (mg/ml) in the GIA well (x-axis) are plotted against % inhibition (y-axis) of P. falciparum 3D7 (A)
or FVO (B) parasites. Each AMA1-specific IgG was tested at three (for U.S. IgGs) or two (for Mali IgGs) different concentrations. All responses below the
limit of detection in ELISA were assigned a value of 2 mg/ml for the analysis.
doi:10.1371/journal.pone.0020947.g001
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volunteers vaccinated with AMA1 (US-total IgG). Interestingly,
the interference effect of non-AMA1 IgG from total IgG pools
with higher titers of AMA1 was higher than those from total IgG
pools with lower titers. However, while the non-AMA1 IgGs
showed this interference in GIA, they did not block binding of
anti-AMA1 antibodies in US-total IgG to AMA1 protein in a
competition ELISA.
In the case of viruses, such as hepatitis C virus (HCV) or human
immunodeficiency virus (HIV), there are studies showing either
monoclonal or polyclonal antibodies can interfere with the effects
of other monoclonal or polyclonal antibodies in a neutralizing
assay [31-35]. In these studies, the antibodies recognize different
epitopes on the same antigen and the mechanism of the
interference may be explained by steric blocking [36] and/or
conformational rearrangement induced by the non-neutralizing
antibody. A similar phenomenon has been reported with the P.
falciparum Merozoite Surface Protein 1 (MSP1), another blood-
stage vaccine candidate. In the case of MSP1, a proportion of anti-
MSP1 antibodies called ‘‘blocking’’ antibodies, which are found in
people living in malaria endemic areas, competes with an anti-
MSP1 monoclonal antibody capable of inhibiting merozoite
invasion of erythrocytes in vitro, as judged by a competition
ELISA and by an MSP1 processing assay [37–39]. However, it is
not clear whether such ‘‘blocking’’ antibodies interfere with the
activity of anti-MSP1 antibody, especially the activity of polyclonal
antibodies, in a biological assay, such as GIA. It has been reported
that human ‘‘blocking’’ antibodies interfere with the invasion-
inhibitory activity of mouse anti-MSP1 monoclonal antibody
(mAb) 12.8, but the same human antibodies did not block the
biological activity of another inhibitory mAb 12.10 [37]. To our
knowledge, non-AMA1 IgG is the only reported antibodies which
have been shown to interfere with the growth-inhibitory activity
induced by human antigen-specific polyclonal antibodies. How-
ever, it is conceivable that similar functional interference effect
exists in antibodies against other malarial antigens, including
MSP1.
In contrast to the cases of HCV, HIV or MSP1, the non-AMA1
IgGs tested in this study showed negligible level of binding to the
AMA1 protein as judged by ELISA (Table 1). In addition, the
non-AMA1 IgGs did not compete with US-total IgG in a
competition ELISA (Figure 5). We tested up to ,10 times greater
Figure 2. Non-AMA1 IgGs show comparable levels of growth-inhibitory activity as the original total IgG pools. Non-AMA1(3D7) (A) or
non-AMA1(FVO) IgGs were tested against P. falciparum 3D7 (A) or FVO (B) parasites at 10 or 20 mg/ml in GIA well. Percent inhibition of non-AMA1
IgG (y-axis) is plotted against the % inhibition of the original total IgG pool (x-axis). The dotted line represents y=x line.
doi:10.1371/journal.pone.0020947.g002
Figure 3. Non-AMA1 IgGs from Malian children reduce the
growth-inhibitory activity of US-total IgG. (A) Four mg/ml of non-
AMA1(3D7) IgGs were tested either by themselves (left side) or with US-
total IgG (right side) using P. falciparum 3D7 parasites. The US-total IgG
was tested alone as a positive control (black bar) (B). Similar study was
performed using non-AMA(FVO) IgGs and P. falciparum FVO parasites.
NS: % inhibition was in the range of 65%. *: no non-AMA1 IgG was
made in this study.
doi:10.1371/journal.pone.0020947.g003
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tested in GIA (Figure 3) where non-AMA1 IgG showed this
interference effect, but still there was no competition observed.
Since the non-AMA1 IgGs had some residual anti-AMA1
antibodies in the final preparation, one may consider the
possibility that the residual antibody in the non-AMA1 IgGs
masked the competition effect. However, we think this is not the
case. When non-AMA1 IgGs were tested at 11–14 mg/ml (which
gave the same ratio of non-AMA1 IgG and US-total IgG as tested
in Figure 3), the amount of anti-AMA1 antibody coming from the
non-AMA1 IgG was less than 5% compared to the one from US-
total IgG. Even at the highest concentration of non-AMA1 IgG
tested (i.e., 133 mg/ml), anti-AMA1 antibody from non-AMA1
IgG was less than 30% compared to the one from US-total IgG.
Therefore, we concluded the competition effect of non-AMA1 was
not obvious if any. These results suggest that either binding
between AMA1 protein and non-AMA1 IgGs was too weak to
detect by conventional ELISA and/or the mechanism of
interference by non-AMA1 IgG is an indirect effect. Not only
the function of AMA1 during the invasion process, but also the
mechanism of invasion inhibition by anti-AMA1 antibodies is still
controversial. Some studies show that a rabbit polyclonal growth-
inhibitory anti-AMA1 antibody disrupts proteolytic processing of
AMA1 [40,41] and other studies with inhibitory mAb or peptide
show that they block complex formation of AMA1 and rhoptry
neck proteins RON2, RON4 and RON5 [42,43]. In our previous
study [27], we have shown that the interfering activity was due to
the malaria-specific IgGs in the non-AMA1 IgGs population.
However, because the growth-inhibitory activity of non-AMA1
IgGs in the previous study was high (the IgGs were collected
mainly from Malian adults), we couldn’t measure the strength of
the interference effect. In this study with IgGs from Malian
children, we could not perform malaria-extract-specific IgG
purification from the non-AMA1 IgGs because of the limited
quantity of blood samples available. On the other hand, as the
intrinsic growth-inhibitory activity of non-AMA1 IgGs from
Figure 4. The correlation between anti-AMA1 antibody levels in the original total IgG pool and the interference effect of the
corresponding non-AMA1 IgG. Anti-AMA1(3D7) (A) or anti-AMA1(FVO) (B) antibody levels (mg/ml) in the original total IgG pools (x-axis) are
plotted against delta % inhibition of non-AMA1 IgGs (y-axis) tested with P. falciparum 3D7 (A) or FVO (B) parasites. Delta % inhibition of each non-
AMA1 IgG was calculated using the data presented in Figure 3 as follows: delta % inhibition = (% inhibition of the US-total IgG alone (black bar in
Figure 3)) - (% inhibition of a mixture of the non-AMA1 IgG and US-total IgG).
doi:10.1371/journal.pone.0020947.g004
Figure 5. Competition ELISA with US-total IgG and non-AMA1 IgGs. (A) A fixed amount of US-total IgG, which gives approximately O.D.
value of 3, was mixed with 3-fold dilutions of non-AMA1(3D7) IgGs from Malian children. The mixtures were tested by ELISA using an AMA1(3D7)-
coated plate and the O.D. values are shown. (B) Similar study was performed using non-AMA(FVO) IgGs and an AMA1(FVO)-coated ELISA plate.
doi:10.1371/journal.pone.0020947.g005
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the interference effect. We found that the interference effect of
non-AMA1 IgG from total IgG pools with higher AMA1 titers was
greater than that from total IgG pools with lower AMA1 titers. We
believe the higher AMA1 titer reflects more malaria exposure,
because the Malian children with higher AMA1 titer also display
higher titers against other malaria antigens such as MSP1 (our
unpublished observation). Therefore, the correlation between anti-
AMA1 antibody levels in the original total IgG pool and the
strength of interference effect in non-AMA1 IgG suggests that the
interference effect is due to antibody against a malaria antigen
other than AMA1. If the interference mechanism of the non-
AMA1 IgGs is indirect, as the ELISA and competition ELISA
results suggest, it is possible that the non-AMA1 IgGs may bind to
RON2, RON4 and/or RON5 first and then may block the ability
of the anti-AMA1 growth-inhibitory antibody to bind to the
critical site of complex formation. Further studies are required to
reveal the mechanism of the interference IgGs, and such studies
may enhance our understanding of the invasion-inhibition
mechanism by human anti-AMA1 polyclonal antibodies.
In the mixture experiment (Figure 3), we used non-AMA1 IgGs
at 4 mg/ml, while the physiological concentration of IgG in
human serum is 10–20 mg/ml. In the previous study where we
prepared non-AMA1 IgGs from Malian adults, 4 and 0.4 mg/ml
of non-AMA1 IgGs were tested. However, 0.4 mg/ml of non-
AMA1 IgGs did not show a clear interference effect [27]. The
result suggests that a certain level of non-AMA1 IgGs is needed to
detect interference effect in this assay. On the other hand, if we use
non-AMA1 IgGs at 10 or 20 mg/ml, several of them show .20%
inhibition by themselves (Figure 2), so that it is difficult to calculate
the interference effect, as the mixture cannot show lower inhibition
than non-AMA1 IgG alone. Therefore, we decided to use the
same 4 mg/ml concentration as the previous study [27]. The
concentration of AMA1-specific IgG in the US-total IgG used for
the mixture experiment was at 133 (for 3D7 parasites) or 202 (for
FVO) mg/ml, and median level of AMA1-specific antibody in
Malian children after immunization was 111.6 mg/ml [28].
Therefore, it is reasonable to assume than non-AMA1 IgGs
interfere with growth-inhibitory activity of AMA1-specific IgG at
physiological ratio (i.e., mix 10–20 mg/ml of non-AMA1 IgGs
with 100 mg/ml AMA1-specific IgG).
This study clearly shows that there are interference IgGs in the
2–3 year old children who are the main targets of a blood-stage
vaccine. From a vaccine development point of view, one of the
other concerns is whether the AMA1 vaccination by itself induces
such interfering IgGs. In our previous study, we did not detect any
interference effect of non-AMA1 IgG from U.S. vaccinees [27].
That study suggests that the AMA1 vaccination per se is unlikely
to induce the interference IgG at least in a malaria naı ¨ve
population. In this study, the volume of plasma from each Malian
child was too small to make sufficient amounts of AMA1-specific
and/or non-AMA1 IgGs for experiments. Even if we collected a
larger amount of plasma from each individual child, it is
practically impossible to differentiate AMA1-specific and/or
non-AMA1 IgG induced by the vaccination from those induced
by a natural infection in children living in a malaria endemic area.
For that reason, it is difficult to exclude the possibility that AMA1
vaccination induces interfering IgGs in the target population.
However, as shown in Figure 4, non-AMA1 IgGs from children
immunized with the AMA1 vaccine showed the same (AMA1-3)
or less (AMA1-1 and AMA1-2) interference than those from
children without AMA1 vaccination with the same AMA1 levels in
the original total IgG pools. Therefore, there is no evidence to
suggest that AMA1 vaccination induced more interfering IgGs in
this study, rather the data from AMA1-1 and AMA1-2 indicates
that the interference antibody may be induced by natural
infection, not by the AMA1 vaccination.
AMA1 is a highly polymorphic protein [44,45] and it is obvious
that polymorphism is one of the major obstacles to make a broadly
effective vaccine [11]. Indeed, when AMA1 vaccines are
administered in malaria naı ¨ve individuals, the anti-AMA1
antibodies induced by vaccination show growth-inhibitory activity
against the homologous strain of parasites, but weaker or no
activity against heterologous strains of parasites, regardless of
adjuvant used [16,19,22]. In this study, we investigated both 3D7
and FVO strains of parasites and the results demonstrate that the
interference effect occurs in both allelic forms of AMA1. However,
we did not test the heterologous combination, e.g., a mixture of
non-AMA1 (3D7) IgGs and US-total IgG tested against FVO
strain of parasites. Because the non-AMA1(3D7) IgGs still had
anti-AMA1(FVO)-allele-specific antibody in the preparation,
which was confirmed by ELISA and GIA (data not shown), it is
very difficult to interpret the result of mixture experiments with
FVO parasites. We tested a tandem purification method (i.e., total
IgGs were applied onto an AMA1(3D7) purification column and
an AMA1(FVO) column sequentially) using rabbit anti-AMA1
antibodies, but there were technical problems with completely
depleting anti-AMA1(3D7) and anti-AMA1(FVO)-allele-specific
antibodies from the total IgGs (data not shown). Further studies
could be conducted to test the cross-reactivity of the interfering
antibodies if enough volume of starting blood materials is
available.
One of the major questions in malaria vaccine development is
what assay can serve as a surrogate for clinical protection. At this
stage, there is no immunological assay proven to be correlated
with clinical protection. As noted above, anti-AMA1 antibodies
induced both by a malaria infection [26,27] and by an AMA1
immunization in malaria naı ¨ve individuals [14,16,19,21–23] show
growth-inhibitory activity, and a recent clinical challenge trial with
AMA1 vaccine in a malaria naı ¨ve population has shown that there
is a significant correlation between in vivo parasite multiplication-
rate and growth-inhibitory activity measured by in vitro GIA in
vaccine recipients (our unpublished observation). In addition,
some epidemiological studies have shown that the total growth-
inhibitory activity (or invasion-inhibition activity) before the
malaria transmission season is significantly associated with a
subsequent malaria risk [46,47]. However, other epidemiological
studies have not shown such associations [48,49]. Therefore, one
may dispute the usage of this assay for vaccine development. These
epidemiological studies did not test the specificity of antibodies. In
addition, interpretation of growth-inhibitory activity of samples
from epidemiological studies for a specific antigen is not
straightforward. As shown in Figure 1, when anti-AMA1-specific
IgGs were separated from total IgG pools of Malian children, they
showed similar activity as anti-AMA1 IgG from U.S. vaccinees.
However, the AMA1-depleted IgG, i.e., non-AMA1 IgG,
displayed the same level of inhibition as the original total IgG
pool (Figure 2). We also observed the same phenomenon in our
previous study [27] where we separated non-AMA1 IgG from
Malian adults’ total IgGs. In addition, another of our studies [28]
showed that pre-incubation of Malian children’s total IgGs with
AMA1 protein did not reduce growth-inhibitory activity induced
by natural infection (even though the total IgGs had higher level of
AMA1 titer), while the pre-incubation did diminish vaccine-
induced activity almost completely. All of the data indicate that the
overall growth-inhibitory activity induced by a natural infection is
not simply the sum of growth-inhibitory activity of individual
antibodies. Our preliminary study shows that there is no additive
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antibody and anti-MSP1 antibody (our unpublished observation).
Furthermore, it is possible that malaria infection induces not only
growth-inhibitory antibodies, but also interfering antibodies in
humans, at least in the case of AMA1, as shown in this study.
While it is difficult to prove whether such non-additive (and/or
interference) effects really occur in vivo, or whether this is just a
limitation of the in vitro assay, in either case the growth-inhibitory
activity of antibodies from a malaria endemic area for a specific
antigen should be interpreted with caution. However, the GIA is
the only functional assay widely used for AMA1-based vaccine
development. If the growth-inhibitory activity measured by the
GIA reflects some mechanism of protection in vivo, the results of
this study suggest that pre-existing anti-malaria immunity may
modulate the efficacy of the AMA1 vaccine. At a minimum, we
believe it is extremely important to take these findings into account
in evaluating immunogenicity of AMA1-based vaccines when a
study is conducted in populations exposed to malaria.
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